Ex vivo fully human skimune platform for compound sensitivity testing

Overview

The Skimune platform by Alcyomics is an innovative ex vivo system designed to evaluate compound sensitivity using a fully human autologous model. By combining skin and peripheral blood mononuclear cells (PBMCs) from the same donor, this platform offers a unique and highly sensitive approach to detecting irritants. This ensures that the sensitivity tests are both accurate and reflective of human responses, making it an invaluable tool for researchers and developers in need of reliable sensitivity testing methodologies.

Technical specifications

Key features:

• Fully human system: Utilizes skin and immune cells from the same donor to maintain an autologous environment.
• High sensitivity: Capable of detecting subtle irritant responses due to the presence of matched immune cells.
• Robust and medium throughput: Designed for efficient testing without compromising the accuracy or reliability of results.
• Validated platform: Employs established histopathological hallmarks to assess compound sensitivity.

Technology readiness level

The Skimune platform is at Technology Readiness Level 9, indicating that it has been fully validated and is ready for commercial use. Alcyomics offers this as a service for testing the sensitivity of compounds, ensuring high reliability and accuracy in results.